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Abstract
Background: Bioresorbable vascular scaffolds (BVS) have emerged as a new treatment option in 
cardiovascular medicine. Nonetheless, there is still limited data on the use of these novel devices in 
patients with acute coronary syndromes (ACS). The purpose of this study was to evaluate the feasibility 
and efficacy of BVS implantation in patients with ACS.
Methods: The present report is a prospective, two-center registry that involved 165 consecutive pa-
tients hospitalized with the diagnosis of ACS and treated with the Absorb BVS (Abbot Vascular, Santa 
Clara, USA). During 1-year, all patients were monitored for the following endpoints: death, myocardial 
infarction (MI), scaffold thrombosis (ST), target lesion revascularization (TLR), target vessel revascu-
larization (TVR) and target vessel failure (TVF), defined as cardiac death, target vessel MI, and TVR.
Results: A total of 165 patients underwent 179 BVS implantations. 94 patients were diagnosed with 
unstable angina (UA; 57.6%), 45 with non-ST-segment elevation myocardial infarction (NSTEMI; 
27.3%) and 26 with ST-segment elevation myocardial infarction (STEMI; 15.7%). Procedural success 
was achieved in all patients with thrombolysis in myocardial infarction flow 3. During a follow-up of 
14.1 ± 8.5 months (median 12.4 months, IQR 8.7 [8.4 to 12.1] months) death occurred in 4 (2.4%) pa-
tients, including 2 (1.3%) cardiac deaths. There was only 1 case of subacute ST (0.66%), without late ST.  
The incidence of MI, TLR, TVR and TVF were: 2.65%, 2.65%, 7.95%, 9.3%, respectively. 
Conclusions: The present results suggest that BVS implantation in ACS patients is feasible and safe in 
highly experienced centers. One-year clinical results are encouraging with a low rate of stent thrombosis. 
(Cardiol J 2018; 25, 4: 479–486)
Key words: acute coronary syndrome, acute myocardial infarction, STEMI, NSTEMI, 
angiography, coronary, bioresorbable devices/polymers
Introduction
Currently, percutaneous coronary intervention 
(PCI) with drug-eluting stent (DES) implantation 
is recognized as the most effective treatment 
for the majority of patients with acute coronary 
syndrome (ACS) [1]. Despite improved long-term 
results, including death, myocardial infarction (MI), 
stent thrombosis and repeat revascularization, the 
placement of metallic stents may be associated 
with some limitations. Permanent presence of 
a metallic platform stimulates inflammatory and 
thrombotic reactions and this, in turn, increases 
predisposition to the development of coronary 
neoatherosclerosis and thrombosis [2, 3]. There 
is also an increased risk of acute and late stent 
malapposition due to stent undersizing, caused 
by vasospasm or thrombus sequestration behind 
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the struts, especially in patients with thrombotic 
lesions [4–6]. Additionally, metallic stents exclude 
the possibility of future surgical revascularization 
of stented segments and may hinder non-invasive 
imaging techniques. 
Efforts focusing on overcoming the forego-
ing disadvantages of permanent metallic stents 
allowed the introduction of the new technology 
of bioresorbable vascular scaffolds (BVS), which 
seems to be a huge step forward in cardiovascular 
medicine [7]. Since the first in-human drug-elut-
ing BVS implantation, which took place in 2006, 
BVS have been shown to be safe and effective in 
stable patients with noncomplex lesions [8–11]. 
Nonetheless, there is still limited data on the use 
of these novel devices in patients presenting with 
ACS, the most pro-thrombotic form of atheroscle-
rosis. Potential advantages of BVS implantation 
may be related to the future vessel lumen enlarge-
ment, plaque volume reduction and stabilization, 
vasomotion restoration as well as elimination of 
some of the triggers for very late stent thrombo-
sis, such as the presence of non-endothelialized 
struts [12, 13]. On the other hand, the increased 
strut thickness of BVS delays endothelialization 
and correlates with flow disturbance [14], carry-
ing an additional risk of scaffold thrombosis (ST) 
[14]. Another potential limitation of scaffolds is 
the increased risk of strut fracture and disruption 
due to overexpansion. For this reason, precise 
pre-dilatation and vessel sizing before BVS im-
plantation and post-dilation following implanta-
tion should be performed, which may be hard to 
achieve in thrombotic lesions [15, 16]. 
The main purpose of this study was to evaluate 
the feasibility, safety and efficacy of BVS implanta-
tion in patients presenting with ACS.
Methods
The present report is a prospective, two-
center registry involving consecutive patients 
hospitalized between December 2012 and October 
2015 with the diagnosis of ACS treated with the 
implantation of BVS. Eligible patients had at least 
one significant coronary artery stenosis, with no 
restrictions as to the number, severity or lesion 
location. All patients underwent PCI with implan-
tation of at least one BVS (Absorb, Abbott Vascu-
lar, Santa Clara, California). The main exclusion 
criteria were: the presence of cardiogenic shock, 
patient life expectancy of less than 1 year, the use 
of metallic stents during the index procedure and 
the target vessel reference diameter < 2.3 mm and 
> 3.7 mm by visual estimate. Detailed exclusion 
criteria are presented in Table 1. 
The scaffold is composed of semicrystalline 
poly-L-lactide (PLLA) and coated with an amor-
phous poly-D, L-lactide (PDLA) polymer eluting 
everolimus, a potent antiproliferative drug. This 
fully bioresorbable scaffold is radio-lucent, thus 
2 platinum markers are placed at each edge of the 
device to allow easy visualization on angiography or 
other imaging modalities [17]. The Absorb BVS is 
a thick-strut scaffold, with the average strut thick-
ness of 157 microns. Currently three diameters 
(2.5, 3.0, 3.5 mm), and five lengths (8, 12, 18, 23, 
28 mm) are available. The decision to use BVS was 
left to the discretion of the operator. 
The PCI procedure was performed accord-
ing to current PCI guidelines. Pre- and post-
dilatation were at the discretion of the opera-
tor. The size of balloon for pre-dilatation was 
selected according to the reference vessel di-
ameter (1:1). Scaffold sizing was based on the 
visual vessel evaluation. The implantation of 
a scaffold was performed with gradual pressure 
increase by 2 atm every 5 s without exceed-
ing the rated burst pressure. During post-dil-
atation non-compliant, high-pressure balloons 
were used with a diameter sized 0.25–0.5 mm 
larger than the scaffold. Each patient naive to 
antiplatelet therapy, received a loading dose of 
300 mg acetylsalicylic acid and 600 mg clopidogrel 
(n = 41; 24.8%) before or during PCI, fol-
lowed by the maintenance daily dose of 75 mg 
of both medications or prasugrel 60 mg p.o. con-
tinued with 10 mg daily dose (n = 3; 1.8%) or 
ticagrelor 180 mg loading dose and continued with 
2 × 90 mg daily dose (n = 121; 73.3%). Duration 
of dual antiplatelet therapy was recommended for 
a minimum of 12 months. Due to available data sug-
Table 1. Exclusion criteria.
Known intolerance to acetylsalicylic acid, heparin, 
PLLA, everolimus, contrast material
Active bleeding or coagulopathy or patients  
on chronic anticoagulation therapy
Poor compliance
Cardiogenic shock
Comorbidity with limited expected survival  
(< 1 year)
Severe tortuous, calcified or angulated coronary 
anatomy of the study vessel
Fibrinolysis prior to PCI
PCI — percutaneous coronary intervention; PLLA — poly-L-lactide acid
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gesting that BVS may require prolonged dual anti-
platelet therapy (DAPT), to mitigate the risk of late 
and very late ST, the decision about the continuation 
of DAPT after 12 months was made individually for 
the patient depending on the thrombosis risk.
A bolus of unfractionated heparin, 100 U/kg 
was administered intravenously during the proce-
dure. The remaining pharmacotherapy was admin-
istered according to the contemporary guidelines.
The data related to baseline clinical character-
istics, procedural and clinical events were collected 
on an electronic database. During the follow-up 
period, clinical data were obtained after 30 days, 
6 months, 1 year and every following year by direct 
contact with patients or telephone interview, ad-
ditionally, a review of medical reports if patients 
had been hospitalized. 
Patients were monitored for the following 
endpoints: death, MI, ST, target lesion revascu-
larization (TLR), target vessel revascularization 
(TVR) and target vessel failure (TVF), defined as 
cardiac death, target vessel MI, and TVR.
ST-segment elevation MI (STEMI) was de-
fined as electrocardiographic ST elevation concom-
itant with characteristic symptoms of myocardial 
ischemia and subsequent release of biomarkers of 
myocardial necrosis [17]. ST-elevation was defined 
as new ST-segment elevation at the J point in two 
or more contiguous leads of > 0.1 mV in all leads 
other than leads V2–V3. For leads V2–V3 the fol-
lowing cut points apply: ≥ 0.2 mV in men ≥ 40 years, 
≥ 0.25 mV in men < 40 years, or ≥ 0.15 mV in 
women. New or presumed new left bundle branch 
block has been considered as STEMI equivalent. 
Non-ST-segment elevation MI (NSTEMI) defini-
tion involved the presence of angina chest pain, 
with the marked elevation of biomarkers of myo-
cardial necrosis with no evidence of ST-segment 
elevation in the electrocardiogram (ECG). Unstable 
angina was considered to be present in patients 
with symptoms of myocardial ischemia and no 
troponin elevation, with or without ECG changes 
indicative of ischemia (e.g., ST segment depression 
or transient elevation or new T wave inversion) 
[18]. Death was defined as all-cause mortality 
during the follow-up period. The ST was defined 
according to the Academic Research Consortium 
definition [19, 20]. TLR was defined as target seg-
ment reintervention including 5 mm proximal and 
distal to the scaffold. Revascularization was consid-
ered clinically indicated if symptoms of myocardial 
ischemia were present, and/or positive stress test, 
electrocardiographic evidence of ischemia at rest, 
and/or > 70% diameter in-lesion stenosis on an-
giography were observed. 
Angiographic success was defined as success-
ful scaffold deployment at the intended site with 
the residual stenosis of less than 30% (visual es-
timation), with thrombolysis in myocardial infarc-
tion (TIMI) flow grade 3. Procedure success was 
defined as angiographic success in the absence of 
in hospital major adverse cardiac events (MACE). 
Statistical analysis
Continuous variables are presented as mean ± 
standard deviation or median (interquartile range 
[IQR]) and categorical variables are presented as 
counts and percentages. The Kaplan-Meier method 
was used to generate cumulative incidence curves for 
composite endpoint. Analysis was carried out using 
the Statistica software, version 13 (StatSoft Poland).
Results 
A total of 165 ACS patients were treated with 
a total of 179 BVS implantation within the study 
period between October 16, 2012, and October 25, 
2015. Of these, 94 patients were diagnosed with un-
stable angina (57.6%), 45 with NSTEMI (27.3%) and 
26 with STEMI (15.7%). Detailed demographic and 
clinical patient characteristics are presented in Table 2.
Procedural success was obtained in all pa-
tients. In 3 cases coronary dissection occurred 
and was successfully covered with an additional 
scaffold. No peri-procedural MACE were reported. 
Pre- and post-dilatation were performed in 94% 
and 81% of patients, respectively. The angiographic 
characteristics of the lesions treated and the pro-
cedure are reported in Table 3.
Complete follow-up was available in 93% of 
patients (n = 151), however data concerning death 
were obtained from province governor’s office for 
all patients. The mean time of observation was 
14.1 ± 8.5 months (median 12.4 months, IQR 
8.7 [8.4 to 12.1] months). During this period 
4 patients died (2.42%), 2 of cardiovascular cause. 
Four patients developed recurrent MI (2.65%), 
2 in hospital (1 with new Q wave formation), 
and the other 2 within 6 months (1 STEMI and 
1 NSTEMI). In 3 cases MI’s were related to the 
target vessel. The composite rate of TVF was 
9.3%. The rate of TLR and TVR was 2.65% (n = 4), 
7.95% (n = 12), respectively. ST occurred in 
1 (0.66%) patient during hospitalization (definite 
sub-acute thrombosis). No more ST occurred at 
follow-up (Table 4). 
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Discussion
The results of this study showed a high device 
and procedural success rate, with a relatively low 
incidence of peri-procedural complications in ACS 
patients treated with BVS. Also 1-year results are 
excellent in this group of patients. 
The use of bioresorbable scaffolds in ACS 
patients carries some risks. Correct vessel and 
scaffold sizing is very important, due to device 
expansion limits, but correct assessment of target 
vessel diameter may be difficult due to spasm or 
the presence of thrombus [21]. Aggressive lesion 
preparation increases the rate of successful device 
delivery and correct expansion, thus pre-dilatation 
is advisable in all patients [22]. However, in set-
tings of ACS such maneuvers carry additional risk 
Table 3. Angiography characteristics.
Single vessel disease 85 (51.5%)
Multivessel disease 81 (49.1%)
Target vessel location:  
LM 7 (4.2%)
LAD 81 (49.1%)
RCA 29 (17.6%)
LCX 33 (20.0%)
Other 18 (10.9%)
Lesion type:  
B1 10 (6.1%)
B2 142 (86.1%)
C 4 (2.4%)
Calcification 9 (5.5%)
Bifurcation lesion 20 (12.1%)
Thrombus 12 (7.3%)
Restenosis 5 (3.0%)
RVD [mm] 2.9 ± 0.3
MLD [mm] 0.1 ± 0.2
Diameter stenosis [%] 88.4 ± 0.07
IVUS 4 (2.4%)
OCT 0 (0%)
QCA 12 (7.3%)
Visual estimate 150 (90.9%)
Total number of scaffolds 179
Mean scaffolds per lesion 1.1
Mean scaffold length per lesion 21.0 ± 7.9
Mean scaffold diameter per lesion 3.0 ± 0.4
Radial approach 50 (30.3%)
Pre-dilatation 154 (94.0%)
Mean pre-dilatation balloon  
diameter [mm]
2.7 ± 0.4
Max pre-dilatation pressure [atm] 12.8 ± 2.0
Post-dilatation 133 (81%)
Mean post-dilatation balloon  
diameter
2.9 ± 0.6
Max post-dilatation pressure [atm] 18.4 ± 2.8
Pre-procedure TIMI-flow:  
0–1 58 (34.9%)
2 50 (30.3%)
3 58 (34.9%)
Post-procedure TIMI-flow:  
0–1 0 (0%)
2 5 (3.0%)
3 160 (97.1%)
In-scaffold (visual estimate):  
Mean lumen diameter 2.8 ± 0.3
MLD 3.0 ± 0.4
Diameter stenosis 0.3 ± 0.01
Complications occurring any time 
during the procedure:
 
MACE 0 (0%)
Dissection 3 (1.8%)
Spasm 0 (0%)
Distal embolism 0 (0%)
No-reflow 0 (0%)
Angiographic success 165 (100%)
Procedure success 165 (100%)
Depicted are counts, number, incidence (%) or mean ± standard 
deviation; IVUS — intravascular ultrasound; LAD — left anterior 
descending artery; LCX — left circumflex artery; LM — left main;  
MACE — major adverse cardiac events; MLD — minimal lumen 
diameter; OCT — optical coherence tomography; RCA — right 
coronary artery; RVD — reference vessel diameter; TIMI — throm-
bolysis in myocardial infarction; QCA — quantitative coronary 
angiography
Table 2. Baseline characteristics.
Age 59.9 ± 10.6
Male 124 (75.1%)
STEMI 26 (15.7%)
NSTEMI 45 (27.3%)
Unstable angina 95 (57.6%)
Cardiovascular history:  
Prior MI 44 (26.7%)
Prior PCI 53 (32.1%)
Prior CABG 8 (4.8%)
Stroke 8 (4.8%)
Cardiovascular risk factors:  
Hypertension 138 (83.6%)
Diabetes mellitus 36 (21.8%)
IDDM 11 (6.7%)
Hyperlipidemia 138 (83.6%)
Smoking, current 67 (40.6%)
Heart failure 77 (46.7%)
NYHA:  
I 28 (16.9%)
II 31 (18.8%)
III 13 (7.9%)
IV 5 (3%)
Peripheral artery disease 16 (9.7%)
Chronic kidney disease (eGFR < 60) 13 (7.9%)
LVEF < 50% 42 (25.4)
Depicted are counts, number, incidence (%) or mean ± standard 
deviation; CABG — coronary artery bypass grafting; eGFR —  
estimated glomerular filtration rate; IDDM — insulin dependent  
diabetes mellitus; LVEF — left ventricular ejection fraction;  
MI — myocardial infarction; NSTEMI — non-ST-segment elevation 
myocardial infarction; NYHA — New York Heart Association,  
PCI — percutaneous coronary intervention; STEMI — ST-segment 
elevation myocardial infarction
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of plaque disruption, thrombus mobilization and 
distal embolism. For this reason, in highly throm-
botic lesions, thrombus aspiration prior to balloon 
inflation seems mandatory [23]. In the present 
study pre-dilatation was performed in as many as 
94% of patients, including 12 cases with thrombus 
visible on angiography. In all these cases, manual 
thrombus aspiration was applied prior to pre-
dilatation. The overall procedural success rate was 
100%, including all cases with evident thrombus. 
Additionally, the presence of thrombus increases 
the risk of acute, as well as late scaffold malappo-
sition. However, in the prospective, multi-centre 
Prague 19 study, the optical coherence tomography 
(OCT) analysis revealed only 1.1% of malapposed 
struts, much less than the number observed in 
the Absorb Cohort B study (3.5%) [24, 25]. Cur-
rently, the most reliable method of vessel sizing 
is OCT, which provides precise vessel and lesion 
measurements, optimal for sizing and positioning 
of the scaffold. Moreover, OCT allows for accurate 
assessment of scaffold apposition after completion 
of the procedure. However, due to limited avail-
ability and costs, OCT is generally underused. 
When quantitative coronary angiography analysis 
alone is applied, maximal vasodilatation with intra-
coronary nitroglycerin injection should be obtained 
prior to measurement. In this study only visual 
estimations have been applied, which represents 
a typical clinical approach in an all-comer popula-
tion of ACS patients. The present results  showed 
that the procedure of BVS implantation, especially 
regarding to pre-, post-dilatation and vessel sizing, 
can be safe and effective when it is performed by 
very experienced operators. 
The rate of post-dilatation in this series was 
high (81%), which corresponds to the current 
opinion of a majority of operators. Post-dilatation 
should be performed with short non-compliant 
balloons, for at least 10–30 s [22]. 
In randomized trials mid and long-term out-
comes of PCI procedures with BVS have been 
assessed predominantly in patients with stable 
coronary disease and relatively simple lesions 
[25–29]. Recently, the preliminary report of pro-
spective has been published, randomized all-comer 
AIDA trial (Amsterdam Investigator–initiateD 
Absorb strategy all-comers trial) which evalu-
ated the efficacy and performance of Absorb BVS 
strategy versus XIENCE family everolimus-eluting 
metallic coronary stent system in the treatment 
of coronary lesions. There was no significant dif-
ference in the rate of TVF between the scaffold 
versus stent strategy (2-year cumulative event 
rates, 11.7% and 10.7%, respectively; hazard ratio 
[HR] 1.12; 95% confidence interval [CI] 0.85–1.48; 
p = 0.43). However, the bioresorbable scaffold 
was associated with a higher incidence of device 
thrombosis (31 patients) than the metallic stent 
(8 patients) through 2 years of follow-up (2-year 
cumulative event rates, 3.5% vs. 0.9%; HR 3.87; 
95% CI 1.78–8.42; p < 0.001) [29]. As opposed 
to randomized trials, registries bring more light 
to the value of bioresorbable technology in all-
comer populations, including patients with ACS. 
In the GHOST-EU, the largest all-comer registry 
to date, BVS proved to be effective in a wide range 
of patients, including 563 patients with ACS. At 
6 months the incidence of target lesion failure 
(TLF, composite of cardiac death, target-vessel 
MI, or clinically driven TLR) reached 4.4%. The 
rate of Academic Research Consortium (ARC) 
definite/probable ST (1.5% at 30 days and 2.1% at 
6 months) was higher when compared to other BVS 
and DES studies [30]. It should be noted that this 
study reflects a very early experience of European 
operators with bioresorbable technology, with an 
overall post-dilatation rate below 50%. The results 
varied widely between centers, mainly due to dif-
ferences in  center experience. The outcomes in 
highly experienced centers were definitely better. 
Notably, the use of intravascular imaging tools was 
relatively rare in the GHOST-EU Registry, which 
might essentially affect outcomes.
A recent large registry published by Puricel 
et al. [31], reported data following BVS implanta-
tion in 1305 unselected patients, including 653 
(50%) patients presented with ACS (19% STEMI), 
Table 4. Results.
N = 151 FU < 30 days Total FU
All cause death 1 (0.61%) 4 (2.42%)
Cardiac death 1 (0.61%) 2 (1.21%)
Any MI 2 (1.32%) 4 (2.65%)
Target vessel MI 2 (1.32%) 3 (1.98%)
Scaffold thrombosis 1 (0.66%) 1 (0.66%)
Target lesion  
revascularization
2 (1.32%) 4 (2.65%)
Target vessel  
revascularization
3 (1.98%) 12 (7.95%)
Target vessel failure 4 (2.65%) 14 (9.27%)
Depicted are counts, number, incidence (%); MI — myocardial  
infarction, FU — follow-up 
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has shown similar results. The rate of probable 
and definite ST was 1.8% at 30 days, 2.3% at 
6 months, and 3.0% at 12 months. In a multivari-
able analysis, impaired left ventricular function 
(p = 0.019) and BVS implantation in ostial lesions 
(p = 0.049) were independently associated with 
ST. In addition, post-procedural minimal lumen 
diameter (MLD) and reference vessel diameter 
were significantly lower in the ST group (p < 0.001 
for both). Authors reported that post-procedural 
MLDs below 2.4 mm (for the 2.5-mm to 3.0-mm 
BVS) and 2.8 mm (for the 3.5-mm BVS) were 
associated with an increased risk of thrombosis. 
Interestingly, the implementation of a BVS-specific 
implantation procedure significantly decreased the 
incidence of 12-month ST from 3.3% to 1.0% (p = 
= 0.035). After propensity score analysis (“early ex-
perience” group vs. “BVS-specific protocol” group) 
this result was maintained (p < 0.012) [31]. ACS 
patients form a special group, where the main con-
cern is the implantation of thick-strut devices into 
lesions with high thrombus burden [32]. Diletti et 
al. [23] presented promising clinical results of BVS 
implantation in 48 STEMI patients at the 30-day 
follow-up. The overall MACE rate was only 2.6%, 
including 1 patient, who developed a non-Q wave 
MI related to a non-target-vessel [23]. Similarly, 
the Prague 19 study has shown high efficacy and 
safety of BVS implantation in STEMI as compared 
to a control group treated with metallic stents. Out 
of 41 patients treated with BVS at 6 months there 
were only 2 (5.0%) events (1 ST in a patient who 
stopped taking all the prescribed medications and 
a small MI due to intra-procedural side branch oc-
clusion), whereas there were 4 (7.02%) events in 
the control [24]. Another registry reported the use 
of BVS in real-world setting. In the Polish National 
Registry, data from 30 interventional centers in 
Poland were collected. Out of 591 patients 52% 
presented with ACS. The results have shown high 
procedural success and a low complication rate with 
dissection in 2.9% of patients, slow-flow in 0.5%, 
no-reflow in 0.17%, and side branch occlusion in 
0.33% [33]. The POLAR ACS study analyzed 100 
patients with ACS treated with BVS implantation. 
At 1-year, 1 MI caused by ST as well as 1 TLR were 
observed [34]. For comparison, the outcomes of 
an all-comers registry have shown the relatively 
high incidence of definite/probable ST (3.1% at 
12 months, all in the first 6 months) in the setting 
of ACS (37.6% of STEMI). The rate of composite 
endpoint (cardiovascular death, any MI, TLR) 
reached 13.5%, including 4 (3%) cardiac deaths, 
4 (3%) STEMIs, 5 (3.8%) NSTEMIs, 9 (6.8%) 
TLRs, and was comparable with all-comer DES 
studies, enrolling ACS patients [35–39]. The ma-
jority of events occurred in the first 6 months [40]. 
Imori et al. [41] have showed that in the setting 
of ACS patients the rates of MACE (composite 
of death, myocardial infarction, TLR) (9.3% vs. 
4.7%, p = 0.003) and stent thrombosis (2.8% vs. 
0.9%, p = 0.01) were significantly higher in BVS 
group compared to EES group. However, the 
authors noticed that the incidence of MACE in 
BVS patients with postdilatation was comparable 
to those observed in EES group (6.0% vs. 4.7%, 
p = 0.23). These differences were mainly driven 
by lower rate of TLR. ST rate was also decreased, 
but not significantly (2.6% vs. 0.9%, p = 0.045). 
In comparison to presented data, these results are 
promising. ST occurred in only 1 (0.66%) patient, 
and the composite rates of TVF was 9.3% at 1-year 
follow-up. Recent evidence from clinical trials have 
shown similar outcomes. 
The 3-year ABSORB II study has had a critical 
impact on BVS technology and has undermined its 
current state of development [28]. The treatment 
with Absorb was associated with a 2-fold increased 
risk of device-oriented clinical events, specifically 
an increased risk of target-vessel MI (7% vs. 1%; 
p = 0.006), as well as increased risk of late ST 
compared with Xience (Abbott Vascular). The 
definite ST occurred in 6 patients who received the 
Absorb compared with no reported cases of defi-
nite or probable stent thrombosis for patients who 
received the Xience stent. Additionally, Absorb did 
not result in an improvement in vasomotor tone 
and was associated with an increase in late lumen 
loss when compared with the Xience everolimus-
eluting metallic stent. The question is what has 
beenlearned from this lesson and  what direction 
of development should now be chosen. 
Regarding conclusions from the BVS, every 
new device should undergo monitored introduction 
and be limited to strictly selected patient groups.
The uture direction for research in BVS technology 
should be focused on several aspects. Reduction of 
strut thickness and introduction of rounder strut 
cross-section will reduce the protrusion of the strut 
and minimize areas of flow disturbance as well as 
recirculation zones. Moreover, faster bioresorption 
without inducing an inflammatory vasculitis will 
result in fast tissue coverage and firm encapsula-
tion of the struts into the vessel wall. As a result, 
thrombogenicity could be decreased. Research on 
the second generation of BVS is underway. 
The results of the present study demonstrated 
the procedural feasibility and efficacy as well as 
484 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 4
clinical safety of BVS implantation in patients pre-
senting with ACS. Nonetheless, due to concerns 
regarding long-term clinical safety all patients after 
BVS implantation should be closely monitored. Ad-
ditionally, data from ongoing trials should be made 
available in the public domain at regular intervals.
Limitations of the study
The present findings are mostly limited by the 
observational nature of a prospective, single-arm 
study. Head-to-head comparison was not performed 
with the standards of treatment. Additionally, the 
follow-up period differed between patients with no 
minimal observation time. The presented clinical 
outcomes are encouraging, but require longer 
follow-up.
Conclusions
The use of BVS in the documented centers 
were feasible in most patients with ACS. One-year 
clinical results are encouraging and were compa-
rable to outcomes reported in patients implanted 
with second-generation DES. Notably, all patients 
were treated in two highly experienced centers. 
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